Link Biologics
Business Coaches
Link Biologics
2nd Floor, London
# Link Biologics
Link Biologics is a London-based biopharmaceutical company pioneering the development of protein therapeutics centred on TSG-6, an endogenous human protein with potent anti-inflammatory and tissue-protective properties. The company leverages decades of research into TSG-6's role in mesenchymal stem cell therapy to create novel drug candidates that address unmet clinical needs.
The company serves patients suffering from inflammatory and degenerative diseases, with particular focus on two major therapeutic areas: Dry Eye Disease (DED) and Wet Age-related Macular Degeneration (AMD). These conditions represent multi-billion-pound global markets characterised by limited treatment options and significant patient suffering.
What distinguishes Link Biologics is its differentiated approach to protein therapeutic design. Rather than blocking single disease pathways like conventional treatments, their TSG-6-based biologics—including their lead candidate Link_TSG6—simultaneously modulate multiple disease mechanisms through anti-inflammatory, tissue-protective and tissue-reparative properties. This multi-pathway approach more closely mimics the body's natural healing processes.
The company's technology functions as a biological rheostat rather than an on/off switch, fine-tuning intrinsic cellular pathways to promote tissue repair whilst regulating inflammation without fibrosis. Their enhanced protein variants demonstrate superior activity compared to native TSG-6, positioning Link Biologics at the forefront of next-generation biologic therapeutics for conditions where existing treatments fall short.
Link Biologics is a London-based biopharmaceutical company pioneering the development of protein therapeutics centred on TSG-6, an endogenous human protein with potent anti-inflammatory and tissue-protective properties. The company leverages decades of research into TSG-6's role in mesenchymal stem cell therapy to create novel drug candidates that address unmet clinical needs.
The company serves patients suffering from inflammatory and degenerative diseases, with particular focus on two major therapeutic areas: Dry Eye Disease (DED) and Wet Age-related Macular Degeneration (AMD). These conditions represent multi-billion-pound global markets characterised by limited treatment options and significant patient suffering.
What distinguishes Link Biologics is its differentiated approach to protein therapeutic design. Rather than blocking single disease pathways like conventional treatments, their TSG-6-based biologics—including their lead candidate Link_TSG6—simultaneously modulate multiple disease mechanisms through anti-inflammatory, tissue-protective and tissue-reparative properties. This multi-pathway approach more closely mimics the body's natural healing processes.
The company's technology functions as a biological rheostat rather than an on/off switch, fine-tuning intrinsic cellular pathways to promote tissue repair whilst regulating inflammation without fibrosis. Their enhanced protein variants demonstrate superior activity compared to native TSG-6, positioning Link Biologics at the forefront of next-generation biologic therapeutics for conditions where existing treatments fall short.
Services offered
protein biologic drug developmentTSG-6 therapeutic researchinflammatory disease treatmentdegenerative disease therapydry eye disease programmewet age-related macular degeneration programmemulti-pathway disease modulationtissue repair and regeneration
Customer reviews
H
Harish Ratna